|
1000
|
Abstract/Summary
|
-
<jats:title>Abstract</jats:title><jats:sec>
<jats:title>Background</jats:title>
<jats:p>PSMA-PET is increasingly used for staging prostate cancer (PCA) patients. However, it is not clear if quantitative imaging parameters of positron emission tomography (PET) have an impact on disease progression and are thus important for the prognosis of localized PCA.</jats:p>
</jats:sec><jats:sec>
<jats:title>Methods</jats:title>
<jats:p>This is a monocenter retrospective analysis of 86 consecutive patients with localized intermediate or high-risk PCA and PSMA-PET before treatment The quantitative PET parameters maximum standardized uptake value (SUV<jats:sub>max</jats:sub>), tumor asphericity (ASP), PSMA tumor volume (PSMA-TV), and PSMA total lesion uptake (PSMA-TLU = PSMA-TV × SUV<jats:sub>mean</jats:sub>) were assessed for their prognostic significance in patients with radiotherapy or surgery. Cox regression analyses were performed for biochemical recurrence-free survival, overall survival (OS), local control, and loco-regional control (LRC).</jats:p>
</jats:sec><jats:sec>
<jats:title>Results</jats:title>
<jats:p>67% of patients had high-risk disease, 51 patients were treated with radiotherapy, and 35 with surgery. Analysis of metric PET parameters in the whole cohort revealed a significant association of PSMA-TV (<jats:italic>p</jats:italic> = 0.003), PSMA-TLU (<jats:italic>p</jats:italic> = 0.004), and ASP (<jats:italic>p</jats:italic> < 0.001) with OS. Upon binarization of PET parameters, several other parameters showed a significant association with clinical outcome. When analyzing high-risk patients according to the primary treatment approach, a previously published cut-off for SUV<jats:sub>max</jats:sub> (8.6) showed a significant association with LRC in surgically treated (<jats:italic>p</jats:italic> = 0.048), but not in primary irradiated (<jats:italic>p</jats:italic> = 0.34) patients. In addition, PSMA-TLU (<jats:italic>p</jats:italic> = 0.016) seemed to be a very promising biomarker to stratify surgical patients.</jats:p>
</jats:sec><jats:sec>
<jats:title>Conclusion</jats:title>
<jats:p>Our data confirm one previous publication on the prognostic impact of SUV<jats:sub>max</jats:sub> in surgically treated patients with high-risk PCA. Our exploratory analysis indicates that PSMA-TLU might be even better suited. The missing association with primary irradiated patients needs prospective validation with a larger sample size to conclude a predictive potential.</jats:p>
<jats:p><jats:italic>Trial registration</jats:italic> Due to the retrospective nature of this research, no registration was carried out.</jats:p>
</jats:sec>
|
|
1000
|
Hinweis
|
-
DeepGreen-ID: 2b97aa87db2d424ba2b01114ad91a901 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
|
